nach oben

Archives of Dermatological Research

Erschienen in:

01.06.2007 | Mini-Review

Scleroderma - news to tell

verfasst von: Beate Eckes, Nicolas Hunzelmann, Pia Moinzadeh, Thomas Krieg

Erschienen in: Archives of Dermatological Research | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Abstract

Scleroderma is a chronic fibrosing disease, in which an early inflammatory reaction precedes the fibrotic response. Systematic analysis of the pathways involved in the development of the disease together with information derived from novel animal models have helped to better understand the mechanisms that trigger and sustain fibrotic reactions.

Abraham DJ, Varga J (2005) Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 26(11):587–595PubMedCrossRef

Adams KM, Nelson JL (2004) Microchimerism: an investigative frontier in autoimmunity and transplantation. Jama 291(9):1127–1131PubMedCrossRef

Arnett FC, Cho M, Chatterjee S, Aguilar MB, Reveille JD, Mayes MD (2001) Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum 44(6):1359–1362PubMedCrossRef

Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K (2005) Involvement of alphavbeta5 integrin-mediated activation of latent transforming growth factor beta1 in autocrine transforming growth factor beta signaling in systemic sclerosis fibroblasts. Arthritis Rheum 52(9):2897–2905PubMedCrossRef

Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, Fraticelli P, Sambo P, Funaro A, Kazlauskas A, Avvedimento EV, Gabrielli A (2006) Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354(25):2667–2676PubMedCrossRef

Brinckmann J, Neess CM, Gaber Y, Sobhi H, Notbohm H, Hunzelmann N, Fietzek PP, Muller PK, Risteli J, Gebker R, Scharffetter-Kochanek K (2001) Different pattern of collagen cross-links in two sclerotic skin diseases: lipodermatosclerosis and circumscribed scleroderma. J Invest Dermatol 117(2):269–273PubMedCrossRef

Carulli MT, Ong VH, Ponticos M, Shiwen X, Abraham DJ, Black CM, Denton CP (2005) Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum 52(12):3772–3782PubMedCrossRef

Crilly A, Hamilton J, Clark CJ, Jardine A, Madhok R (2002) Analysis of transforming growth factor beta1 gene polymorphisms in patients with systemic sclerosis. Ann Rheum Dis 61(8):678–681PubMedCrossRef

Denton CP, Black CM (2004) Scleroderma–clinical and pathological advances. Best Pract Res Clin Rheumatol 18(3):271–290PubMed

10.

Denton CP, Humbert M, Rubin L, Black CM (2006) Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 65(10):1336–1340PubMedCrossRef

11.

Distler JH, Jungel A, Caretto D, Schulze-Horsel U, Kowal-Bielecka O, Gay RE, Michel BA, Muller-Ladner U, Kalden JR, Gay S, Distler O (2006) Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T cells. Arthritis Rheum 54(1):214–225PubMedCrossRef

12.

Eckes B, Zweers MC, Zhang ZG, Hallinger R, Mauch C, Aumailley M, Krieg T (2006) Mechanical Tension and Integrin alpha2beta1 Regulate Fibroblast Functions. J Invest Dermatol 126(Suppl):66–72

13.

Galindo M, Santiago B, Rivero M, Rullas J, Alcami J, Pablos JL (2001) Chemokine expression by systemic sclerosis fibroblasts: abnormal regulation of monocyte chemoattractant protein 1 expression. Arthritis Rheum 44(6):1382–1386PubMedCrossRef

14.

Gardner H, Shearstone JR, Bandaru R, Crowell T, Lynes M, Trojanowska M, Pannu J, Smith E, Jablonska S, Blaszczyk M, Tan FK, Mayes MD (2006) Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 54(6):1961–1973PubMedCrossRef

15.

Harris ML, Rosen A (2003) Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol 15(6):778–784PubMedCrossRef

16.

Hasegawa M, Fujimoto M, Kikuchi K, Takehara K (1997) Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol 24(2):328–332PubMed

17.

Hata R, Akai J, Kimura A, Ishikawa O, Kuwana M, Shinkai H (2000) Association of functional microsatellites in the human type I collagen alpha2 chain (COL1A2) gene with systemic sclerosis. Biochem Biophys Res Commun 272(1):36–40PubMedCrossRef

18.

Hinz B (2006) Masters and servants of the force: the role of matrix adhesions in myofibroblast force perception and transmission. Eur J Cell Biol 85(3–4):175–181PubMedCrossRef

19.

Horwitz DA (2006) Transforming growth factor-beta: taking control of T cells’ life and death. Immunity 25(3):399–401PubMedCrossRef

20.

Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Fujimoto M, Grotendorst GR, Takehara K (1996) Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Invest Dermatol 106(4):729–733PubMedCrossRef

21.

Isogai Z, Ono RN, Ushiro S, Keene DR, Chen Y, Mazzieri R, Charbonneau NL, Reinhardt DP, Rifkin DB, Sakai LY (2003) Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem 278(4):2750–2757PubMedCrossRef

22.

Jimenez SA, Artlett CM (2005) Microchimerism and systemic sclerosis. Curr Opin Rheumatol 17(1):86–90PubMedCrossRef

23.

Jinnin M, Ihn H, Yamane K, Tamaki K (2004) Interleukin-13 stimulates the transcription of the human alpha2(I) collagen gene in human dermal fibroblasts. J Biol Chem 279(40):41783–41791PubMedCrossRef

24.

Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M (1998) Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol 110(1):47–51PubMedCrossRef

25.

Kessler D, Dethlefsen S, Haase I, Plomann M, Hirche F, Krieg T, Eckes B (2001) Fibroblasts in mechanically stressed collagen lattices assume a “synthetic” phenotype. J Biol Chem 276(39):36575–36585PubMedCrossRef

26.

Kulkarni AB, Huh CG, Becker D, Geiser A, Lyght M, Flanders KC, Roberts AB, Sporn MB, Ward JM, Karlsson S (1993) Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A 90(2):770–774PubMedCrossRef

27.

Langholz O, Rockel D, Mauch C, Kozlowska E, Bank I, Krieg T, Eckes B (1995) Collagen and collagenase gene expression in three-dimensional collagen lattices are differentially regulated by alpha 1 beta 1 and alpha 2 beta 1 integrins. J Cell Biol 131(6 Pt 2):1903–1915PubMedCrossRef

28.

LeRoy EC (1974) Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 54(4):880–889PubMedCrossRef

29.

LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15(2):202–205PubMed

30.

LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28(7):1573–1576PubMed

31.

Ong VH, Evans LA, Shiwen X, Fisher IB, Rajkumar V, Abraham DJ, Black CM, Denton CP (2003) Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse. Arthritis Rheum 48(7):1979–1991PubMedCrossRef

32.

Pannu J, Gardner H, Shearstone JR, Smith E, Trojanowska M (2006) Increased levels of transforming growth factor beta receptor type I and up-regulation of matrix gene program: A model of scleroderma. Arthritis Rheum 54(9):3011–3021PubMedCrossRef

33.

Ruzek MC, Jha S, Ledbetter S, Richards SM, Garman RD (2004) A modified model of graft-versus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum 50(4):1319–1331PubMedCrossRef

34.

Shi-Wen X, Rodriguez-Pascual F, Lamas S, Holmes A, Howat S, Pearson JD, Dashwood MR, du Bois RM, Denton CP, Black CM, Abraham DJ, Leask A (2006) Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: evidence of an autocrine endothelin loop operating through the endothelin A and B receptors. Mol Cell Biol 26(14):5518–5527PubMedCrossRef

35.

Siracusa LD, McGrath R, Ma Q, Moskow JJ, Manne J, Christner PJ, Buchberg AM, Jimenez SA (1996) A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res 6(4):300–313PubMedCrossRef

36.

Sonnylal S, Denton CP, Zheng B, Keene DR, He R, Adams HP, Vanpelt CS, Geng YJ, Deng JM, Behringer RR, de Crombrugghe B (2006) Postnatal induction of transforming growth factor beta signaling in fibroblasts of mice recapitulates clinical, histologic, and biochemical features of scleroderma. Arthritis Rheum 56(1):334–344CrossRef

37.

Tan FK, Wang N, Kuwana M, Chakraborty R, Bona CA, Milewicz DM, Arnett FC (2001) Association of fibrillin 1 single-nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. Arthritis Rheum 44(4):893–901PubMedCrossRef

38.

Tan FK, Tercero GM, Arnett FC, Wang N, Chakraborty R (2003) Examination of the possible role of biologically relevant genes around FBN1 in systemic sclerosis in the Choctaw population. Arthritis Rheum 48(11):3295–3296PubMedCrossRef

39.

Tan FK, Hildebrand BA, Lester MS, Stivers DN, Pounds S, Zhou X, Wallis DD, Milewicz DM, Reveille JD, Mayes MD, Jin L, Arnett FC Jr (2005) Classification analysis of the transcriptosome of nonlesional cultured dermal fibroblasts from systemic sclerosis patients with early disease. Arthritis Rheum 52(3):865–876PubMedCrossRef

40.

Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA (2002) Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 3(5):349–363PubMedCrossRef

41.

Trojanowska M (2004) What did we learn by studying scleroderma fibroblasts?. Clin Exp Rheumatol 22(3 Suppl 33):S59–S63PubMed

42.

Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, McCalmont TH, Brown PO, Botstein D, Connolly MK (2003) Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci U S A 100(21):12319–12324PubMedCrossRef

43.

Wollheim FA (2005) Classification of systemic sclerosis. Visions and reality. Rheumatology (Oxford) 44(10):1212–1216CrossRef

44.

Wynn TA (2004) Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 4(8):583–594PubMedCrossRef

45.

Yamakage A, Kikuchi K, Smith EA, LeRoy EC, Trojanowska M (1992) Selective upregulation of platelet-derived growth factor alpha receptors by transforming growth factor beta in scleroderma fibroblasts. J Exp Med 175(5):1227–1234PubMedCrossRef

46.

Yamamoto T, Takagawa S, Katayama I, Yamazaki K, Hamazaki Y, Shinkai H, Nishioka K (1999) Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 112(4):456–462PubMedCrossRef

47.

Zhang Y, McCormick LL, Desai SR, Wu C, Gilliam AC (2002) Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: cutaneous cytokines, chemokines, and immune cell activation. J Immunol 168(6):3088–3098PubMed

48.

Zhou L, Askew D, Wu C, Gilliam AC (2007) Cutaneous gene expression by DNA microarray in murine slerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol 127(2):281–292PubMedCrossRef

Titel: Scleroderma - news to tell
verfasst von: Beate Eckes
Nicolas Hunzelmann
Pia Moinzadeh
Thomas Krieg
Publikationsdatum: 01.06.2007
Verlag: Springer-Verlag
Erschienen in: Archives of Dermatological Research / Ausgabe 3/2007
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI: https://doi.org/10.1007/s00403-007-0756-7

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Dermatologie

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Isotretinoin: Risiko für schwere Laboranomalien „marginal erhöht“

08.05.2024 Akne Nachrichten

Die Aknetherapie mit Isotretinoin kann einen Anstieg von Leberenzymen und Blutfetten verursachen. Das Risiko für schwere Störungen ist laut einer Forschungsgruppe der Universität Lübeck aber nur marginal erhöht und auf einen engen Zeitraum konzentriert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2007

Lack of association between NPHS2 gene polymorphisms and Henoch-Schönlein purpura nephritis

German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version)

Relevance of the low-affinity type of the Fcγ-receptor IIIa-polymorphism in bullous pemphigoid

Intraperitoneal injection of pemphigus vulgaris-IgG into mouse depletes epidermal keratinocytes of desmoglein 3 associated with generation of acantholysis

Netherton syndrome: mutation analysis of two Taiwanese families